Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation is a research paper published in Journal for ImmunoTherapy of Cancer (2023). On theSindex it has a DataRank of 0. It has been cited 62 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Comprehensive Cancer Center Düsseldorf
Grant: N/A
National Cancer Institute
Grant: P30-CA046934
V Foundation for Cancer Research
Grant: V2021-013
Bundesministerium für Bildung und Forschung
Grant: 01ZX1401B
Bundesministerium für Bildung und Forschung
Grant: 03VP0731
Morgan Adams Foundation
Grant: 2380102
Cancer League of Colorado
Grant: 25B0712
Deutsche Krebshilfe
Grant: 110663
Deutsche Krebshilfe
Grant: 111537
Deutsche Krebshilfe
Grant: 70112951
Deutsche Krebshilfe
Grant: P-91650709
American Cancer Society-IRG
Grant: 16-184-56
Andrew McDonough B+ Foundation
Grant: 612617
NCI NIH HHS
Grant: P30 CA046934
NIH HHS
Grant: S10 OD023485
NIH HHS
Grant: S10 OD027023
NCI NIH HHS
Grant: P30 CA014236
National Institutes of Health
Grant: 3P30CA046934-20S2
Cancer Center Support Grant
Fields of Study
MeSH Terms
Keywords